WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 596696
Description: L 767679 is a fibrinogen receptor antagonist.
MedKoo Cat#: 596696
Name: L 767679
Chemical Formula: C20H24N4O4
Exact Mass: 384.1798
Molecular Weight: 384.43
Elemental Analysis: C, 62.49; H, 6.29; N, 14.57; O, 16.65
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: L 767679; L-767679; L767679;
IUPAC/Chemical Name: (S)-3-(2-(1-oxo-7-(piperazin-1-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetamido)pent-4-ynoic acid
InChi Key: QTVKUFZTCJLGEJ-OAHLLOKOSA-N
InChi Code: InChI=1S/C20H24N4O4/c1-2-15(11-19(26)27)22-18(25)13-24-8-5-14-3-4-16(12-17(14)20(24)28)23-9-6-21-7-10-23/h1,3-4,12,15,21H,5-11,13H2,(H,22,25)(H,26,27)/t15-/m1/s1
SMILES Code: C#C[C@@H](NC(CN(CCC1=C2C=C(N3CCNCC3)C=C1)C2=O)=O)CC(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 384.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999 Jul 15;94(2):587-99. PubMed PMID: 10397726.
2: Prueksaritanont T, DeLuna P, Gorham LM, Ma B, Cohn D, Pang J, Xu X, Leung K, Lin JH. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab Dispos. 1998 Jun;26(6):520-7. PubMed PMID: 9616186.
3: Prueksaritanont T, Gorham LM, Yeh KC. Analysis of metabolite kinetics by deconvolution and in vivo-in vitro correlations of metabolite formation rates: studies of fibrinogen receptor antagonist ester prodrugs. J Pharm Sci. 1997 Dec;86(12):1345-51. PubMed PMID: 9423143.
4: Prueksaritanont T, Gorham LM, Breslin MJ, Hutchinson JH, Hartman GD, Vyas KP, Baillie TA. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate. Drug Metab Dispos. 1997 Aug;25(8):978-84. PubMed PMID: 9280406.